ADPT01C
Total Payments
$49,597
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $49,597 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49,597 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE IB, MULTICENTER, OPEN-LABEL DOSE ESCALATION AND EXPANSION PLATFORM STUDY OF SELECT DRUG COMBINATIONS IN ADULT PATIENTS WITH ADVANCED OR METASTATIC BRAF V600 COLORECTAL CANCER | Novartis Pharmaceuticals Corporation | $49,597 | 0 |
Top Doctors Receiving Payments for ADPT01C
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $49,597 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $49,597
- Total Doctors 0
- Transactions 4
About ADPT01C
ADPT01C is a drug associated with $49,597 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $49,597 was paid across 4 transactions to 0 doctors.
The most common payment nature for ADPT01C is "Unspecified" ($49,597, 100.0% of total).
ADPT01C is associated with 1 research study, including "A PHASE IB, MULTICENTER, OPEN-LABEL DOSE ESCALATION AND EXPANSION PLATFORM STUDY OF SELECT DRUG COMBINATIONS IN ADULT PATIENTS WITH ADVANCED OR METASTATIC BRAF V600 COLORECTAL CANCER" ($49,597).